Sellas, Merck to collaborate on Phase I/II trial in cancer

Sellas Life Sciences Group Ltd. (Hamilton, Bermuda) said it will partner with Merck & Co. Inc. (NYSE:MRK) to conduct a Phase I/II trial of its galinpepimut-S in combination with Merck's Keytruda pembrolizumab to treat Wilms tumor-1 (WT1)-positive relapsed or refractory cancers, including colorectal, ovarian, small cell lung and triple-negative breast cancers and acute myelogenous leukemia (AML).

Galinpepimut-S is a vaccine comprising Wilms tumor 1 (WT1) peptides administered in combination with an adjuvant and immune modulator. Sellas has rights to galinpepimut-S from Memorial Sloan Kettering Cancer Center...